genuine question about sequence that I am slightly embarrassed to ask
genuine question about sequence that I am slightly embarrassed to ask. I would rather ask a basic question now than get this wrong quietly for two months.
Purity by area percent tells you the sample is homogeneous. Mass spectrometry tells you what the homogeneous thing is. For a short peptide, the second question is the one worth paying for.
The published literature is overwhelmingly preclinical, largely in rodent models. Translating a rodent result into a human expectation is not a small step, and almost every confident claim here takes it silently.
Short peptides in solution are subject to hydrolysis and, depending on sequence, oxidation. Storage state and time in solution are practical variables that this board almost never discusses.
Please do not ask me what dose you should be on. I genuinely do not know and neither does anyone else here.
best — the order this archive was captured in
Research-use-only material is not approved for human use. In this board that is not a formality — it is the reason the clinical evidence base is as thin as it is.
Disagree — that is a rodent study and you are stating it as a human effect. The distance between those is the entire argument.
Not convinced. A high purity figure with no identity confirmation tells you the sample is homogeneous, not that it is what you ordered.
Has anyone posted an independent result on that batch?
It is a fifteen-residue peptide with a published sequence, which makes synthesis straightforward and makes identity verification the meaningful test rather than an optional extra.
Kept a reconstituted vial too long out of curiosity and learned something about solution stability I would rather have read.
Push back: "no reported harms" in a literature with almost no human trials is not a safety finding.
Reconstituted or powder, and how long has it been in solution?
Correction: that study was in rodents. Worth stating explicitly since the thread has been reading it as clinical.
Agreed. Identity is the question here. A short peptide can be synthesised by almost anyone and the sequence is what you are actually buying.
short peptides are cheap, which cuts both ways
Regulatory classification differs between jurisdictions and has changed in several of them recently. Any answer to a status question needs a place and a date attached.
That claim traces back to a single preclinical paper that says something considerably narrower.
research-use-only means not approved for human use, and here that covers everything
ask for the mass spectrum, not just the purity number
preclinical enthusiasm is not clinical evidence
preclinical enthusiasm is not clinical evidence
Adding the standing caveat — research material is not approved for human use, wherever you are.
Small fix — fifteen residues, not seventeen. The sequence is public and easy to check.
stability in solution is the practical question nobody asks
Which paper is that claim from, and was it in humans?
Agreed — cheap to make is a double-edged fact and it explains a lot about this corner of the market.
This. Mass spectrometry for identity, not just an area percent, because a pure something-else is still something else.
Careful. Regulatory status differs by jurisdiction and has changed; a confident global statement is going to be wrong somewhere.
Went and read the primary rodent papers after arguing about a summary for a week. They are much narrower than the threads suggest.
- 1ask for the mass spectrum, not just the purity number10 comments in this branch · started by u/nikhil_lindqvist